← All trials
NCT05845489
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 9, 2023
- Primary completion
- Mar 31, 2030
- Completion date
- Mar 31, 2030
- First posted
- May 6, 2023
- Last posted
- May 11, 2023
- Enrollment
- 9930
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Seoul National UniversityLead sponsor
- Hanyang UniversityCollaborator
- Seoul National UniversityReponsible party - principal investigator
- Seoul National UniversityStudy chair
- Kangbuk Samsung HospitalCollaborator
- Wonju Christian HospitalCollaborator
- Hallym UniversityCollaborator
- Hallym UniversityCollaborator
- Keimyung UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.